Japan's Kyowa Hakko Kirin Tests New Antibody Type For Many Cancers
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin of Japan says it has begun U.S. clinical trials on a cancer drug that works similarly to targeted antibodies, but without their side effects, such as hair loss. The firm hopes to have the drug on the market late next year. The drug is based on a newly discovered synthetic compound that interferes with a protein responsible for the proliferation of many types of cancer cells. The company also is counting on the drug to provide the benefits of antibodies, but with a low-cost manufacturing process unlike the normal process that requires expensive and special manufacturing equipment. (Click here for more - a subscription may be required